Promising preclinical data
Our cell therapies for cartilage regeneration and wound healing are supported by promising preclinical data from human cells
Our cell therapies for cartilage regeneration and wound healing are supported by promising preclinical data from human cells
Figure left (top) shows Alcian blue staining of chondrocytes generated from human skin fibroblasts using our innovative culture method, with the chondrocytes staining positive for Alcian blue, in contrast to the human skin fibroblast control, which stained negative.
Figure left (bottom) illustrates the characterization of spheroid-derived chondrocytes generated using out innovative culture method, through immunofluorescence staining, using specific markers for human chondrocytes.
Transforming the future of wound care with an innovative cell therapy program designed to accelerate and improve the healing process for skin wounds
The therapeutic application of Mesenchymal Stem Cells (MSCs) and Keratinocyte Stem Cells has been shown to enhance and accelerate wound healing in clinical settings. However, these stem cells are rare and challenging to isolate and expand for therapeutic use, limiting their availability for widespread treatment.
At Chiron, we are addressing these challenges by providing a scalable, efficient, and safe solution, making advanced stem cell therapies more accessible to patients worldwide.
Human dermal fibroblasts (top) and keratinocyte-derived spheroids (bottom), generated using our innovative approach, possess mesenchymal stem cell and keratinocyte stem cell properties.
We aim to conduct further proof-of-concept studies before planning first-in-human trials.